Testing effectiveness (Phase 2)Study completedNCT03866967What this trial is testingAnti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal CarcinomaWho this might be right forNasopharyngeal Carcinoma Akeso 130
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07022301What this trial is testingSintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 TherapyWho this might be right forSmall Cell Lung Cancer Extensive StageResistance to Immunotherapy First Affiliated Hospital of Wannan Medical College 25
Testing effectiveness (Phase 2)Study completedNCT03463681What this trial is testingCaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinomaWho this might be right forMetastatic Renal Cell Carcinoma Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 49
Not applicableLooking for participantsNCT06887348What this trial is testingAssess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3Who this might be right forMelanomaMetastatic MelanomaAdvanced Solid Tumor+1 more Replimune Inc. 50
Testing effectiveness (Phase 2)UnknownNCT03972722What this trial is testingStudy of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical CancerWho this might be right forCervical Cancer Guangzhou Gloria Biosciences Co., Ltd. 89
Early research (Phase 1)Study completedNCT03547037What this trial is testingEvaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid CancersWho this might be right forNeoplasm Janssen Pharmaceutical K.K. 22
Not applicableNot Yet RecruitingNCT06682247What this trial is testingA Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal CancerWho this might be right forColorectal Cancer Metastatic Feng Wang 200
Not applicableLooking for participantsNCT06154668What this trial is testingProfiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma PatientsWho this might be right forMelanoma University Hospital, Grenoble 707
Testing effectiveness (Phase 2)Looking for participantsNCT06981325What this trial is testingEvaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) PatientsWho this might be right forBasal Cell Carcinoma (BCC)First Line Treatment Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 34
Testing effectiveness (Phase 2)Study completedNCT04526899What this trial is testingInvestigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of TreatmentWho this might be right forMelanoma Stage IIIMelanoma Stage IVUnresectable Melanoma BioNTech SE 184
Testing effectiveness (Phase 2)UnknownNCT03250962What this trial is testingSHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin LymphomaWho this might be right forHodgkin Lymphoma Chinese PLA General Hospital 280
Early research (Phase 1)Study completedNCT03158935What this trial is testingThe ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) TrialWho this might be right forAdvanced Ovarian CancerMalignant Melanoma University Health Network, Toronto 8
Testing effectiveness (Phase 2)Ended earlyNCT03645876What this trial is testingSHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal CancerWho this might be right forMetastatic Colorectal Cancer Jiangsu HengRui Medicine Co., Ltd. 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT05599789What this trial is testingPembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)Who this might be right forNon Small Cell Lung Cancer Metastatic Peking Union Medical College Hospital 47
Testing effectiveness (Phase 2)UnknownNCT03638375What this trial is testingTIL and Anti-PD1 in Metastatic MelanomaWho this might be right forToxicity, DrugAdverse Drug EventEffects of Immunotherapy Leiden University 34
Testing effectiveness (Phase 2)Study completedNCT04444167What this trial is testingAnti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular CarcinomaWho this might be right forHepatocellular Carcinoma Akeso 59
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05982522What this trial is testingIN10018 Combination Therapy in Previously-treated Solid TumorsWho this might be right forSolid Tumor InxMed (Shanghai) Co., Ltd. 72
Early research (Phase 1)WithdrawnNCT04799431What this trial is testingNeoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal CancerWho this might be right forPancreatic Cancer MetastaticColorectal Cancer Metastatic Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing effectiveness (Phase 2)Looking for participantsNCT04977375What this trial is testingTrial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent GlioblastomaWho this might be right forGlioblastoma Multiforme Chirag G. Patil 10
Testing effectiveness (Phase 2)Looking for participantsNCT06865339What this trial is testingThoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung CancerWho this might be right forNSCLCLocally Advanced Nitin Ohri 76